. Wounds UK 2007;3:58-69.

O’Donnell et al 47S

14. Simka M, Majewski E. The social and economic burden of venous leg
ulcers: Focus on the role of micronized puriﬁed ﬂavonoid fraction
adjuvant therapy. Am J Clin Dermatol 2003;4:573-81.
15. Van Gent BW, Wilschut ED, Wittens CW. Management of venous
ulcer disease. BMJ 2010;341:c6045.
16. Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L,
Grifﬁths RI. Medical costs of treating venous stasis ulcers; evidence
from a retrospective cohort study. Vasc Med 1999;4:1-7.
17. Ma H, O’Donnell TF Jr, Rosen NA, Iafrati MD. The real costs of
treating venous ulcers in a contemporary vascular practice [published
online ahead of print June 24, 2014]. J Vasc Surg: Venous and Lym
Dis doi: 10.1016/j.jvsv.2014.04.006.
18. O’Donnell TF, Balk EM. The need for an Intersociety Consensus
Guideline for venous ulcer. J Vasc Surg 2011;54:83S-90S.
19. Olson JM, Raugi GJ, Nguyen VQ, et al. Guideline concordant venous
ulcer care predicts healing in a tertiary care Veterans Affairs Medical
Center. Wound Repair Regen 2009;17:666-70.
20. McGuckin M, Waterman R, Brooks J, Cherry G, Porten L, Hurley S,
et al. Validation of venous leg ulcer guidelines in the United States
and United Kingdom. Am J Surg 2002;183:132-7.
21. Nelzen O. Fifty percent reduction in venous ulcer prevalence is
achievabledSwedish